EGFR (Epidermal Growth Factor Receptor) Exon 19 Deletion Mutation

Also known as: EGFR Exon 19 Deletion Mutation / EGFR exon 19 deletion / EGFR gene mutation / Epidermal growth factor receptor gene mutation

Drug	Drug Name	Drug Description
DB08916	Afatinib	An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy.
DB11963	Dacomitinib	A medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution.
DB05578	Ramucirumab	An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.

Drug	Drug Name	Target	Type
DB08916	Afatinib	Epidermal growth factor receptor	target
DB08916	Afatinib	Receptor tyrosine-protein kinase erbB-2	target
DB08916	Afatinib	Receptor tyrosine-protein kinase erbB-4	target
DB08916	Afatinib	P-glycoprotein 1	transporter
DB08916	Afatinib	ATP-binding cassette sub-family G member 2	transporter
DB11963	Dacomitinib	Cytochrome P450 2D6	enzyme
DB11963	Dacomitinib	Serum albumin	carrier
DB11963	Dacomitinib	Cytochrome P450 3A4	enzyme
DB11963	Dacomitinib	Cytochrome P450 2C9	enzyme
DB11963	Dacomitinib	UDP-glucuronosyltransferase 1-1	enzyme
DB11963	Dacomitinib	P-glycoprotein 1	transporter
DB11963	Dacomitinib	ATP-binding cassette sub-family G member 2	transporter
DB11963	Dacomitinib	Solute carrier family 22 member 1	transporter
DB11963	Dacomitinib	Epidermal growth factor receptor	target
DB05578	Ramucirumab	Vascular endothelial growth factor receptor 2	target

Drug	Drug Name	Phase	Status	Count
DB00958	Carboplatin	1	Terminated	1
DB09330	Osimertinib	1	Terminated	1
DB00642	Pemetrexed	1	Terminated	1
DB09330	Osimertinib	1 / 2	Active Not Recruiting	1
DB00112	Bevacizumab	2	Completed	1
DB00530	Erlotinib	2	Completed	1
DB12257	Platinum	3	Active Not Recruiting	1